Searched for
MANKIND PHARMA STOCK
These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...- Ipca Laboratories among 5 stocks showing bullish RSI upswingFive Nifty500 stocks, including Leela Palaces, Eris Lifesciences, Indian Bank, Mankind Pharma, and Ipca Laboratories, showed bullish moment...
- Ahead of Market: 10 things that will decide stock market action on WednesdayDomestic equity benchmarks ended lower on Tuesday, snapping a three-session rally amid profit booking in financial, realty and consumer sto...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Godfrey Phillips India among 5 F&O stocks with a sharp rise in futures open interestFive NSE F&O stocks witnessed sharp futures open interest buildup on May 20, led by PI Industries and PB Fintech, indicating rising trader ...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Red alert: 15 stocks most vulnerable to FII selling as DIIs refuse to step inForeign institutional investors have divested approximately $53 billion from Indian equities since September 2024, leading to significant o...
- Is your portfolio FII-proof? 7 stocks Jefferies says can defy the $53 billion foreign selloffForeign investors have divested $53 billion from Indian equities since late 2024, leading to underperformance against emerging markets. Dom...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Buy capital goods on dips, stay cautious on IT and consumption: Sudip BandyopadhyayMarket expert Sudip Bandyopadhyay outlines investment strategies across key sectors. He sees opportunities in State Bank of India and a gen...
- Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...
- Rupee at 95, crude at $120+: Why India's markets are flying blind into a stormMarket expert Sudip Bandyopadhyay warns Indian markets face significant risks. High oil prices and a potential monsoon deficit are major co...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...
- Mankind Pharma shares jump 2% as Morgan Stanley initiates coverage with Overweight call. Check target, upsideMankind Pharma share price surged 2% after Morgan Stanley initiated coverage with an 'Overweight' rating and a Rs 2,500 target price, citin...
- Mankind Pharma to raise Rs 10,000 crore through NCDs, CPs to fund BSV dealThe company will raise up to Rs 5,000 crore through non-convertible debentures (NCDs) maturing in up to 48 months, according to a regulator...
- Mankind Pharma board approves raising Rs 10,000 crore through NCDsThe board has established a fundraising committee and granted them the authority to manage all aspects of raising funds, such as deciding t...
- Mankind Pharma stock falls 3% as PE investors likely sell 1.3 crore sharesPE firm ChrysCapital's affiliate entity Beige Ltd was reported to have issued a term sheet via its broker to sell up to 1.16 crore shares o...
- Mankind Pharma shares jump 9% post Q1 earnings. Should you buy?The domestic business reported a robust 14% YoY growth in the quarter. The secondary sales saw an impressive growth of 12.5%, thereby outpe...
- Mankind Pharma draws rush of buy calls on 57% jump since IPOInvestors are scrambling to purchase shares in drug and condom maker, Mankind Pharma Ltd., which has had the most analyst coverage of any n...
Load More
